ITEM VIEW

Experience with adjunctive corticosteriods in managing tuberculous pericarditis

dc.contributor.authorReuter, Helmuth
dc.contributor.authorBurgess, Lesley J.
dc.contributor.authorLouw, Vernon J.
dc.contributor.authorDoubell, Anton F.
dc.date.accessioned2012-01-23T15:46:57Z
dc.date.available2012-01-23T15:46:57Z
dc.date.issued2006-10
dc.identifier.citationReuter, H., Burgess, L.J., Louw, V.J. & Doubell, A.F. 2006. Experience with adjunctive corticosteroids in managing tuberculous pericarditis. Cardiovaascular Journal of South Africa, 17(5):233-238en_ZA
dc.identifier.issn1680-0745 (online)
dc.identifier.issn1995-1892 (print)
dc.identifier.urihttp://hdl.handle.net/10019.1/19355
dc.descriptionThe original publication is available at http://www.cvja.co.za/en_ZA
dc.description.abstractObjectives: To compare the efficacy of intrapericardial corticosteroid therapy to either oral corticosteroid therapy or intrapericardial placebo in addition to closed pericardiocentesis and anti-tuberculous therapy in patients with tuberculous pericarditis. Methods: Patients with large pericardial effusions requiring pericardiocentesis were included. A short-course anti-tuberculous regimen was initiated and patients were randomised to one of three treatment groups: 200 mg intrapericardial triamcinolone hexacetonide; oral prednisone plus intrapericardial placebo; or 5 ml intrapericardial 0.9% saline (placebo). Patients were followed up for at least one year. Results: Fifty-seven patients were included in the study; 21 tested HIV positive (36.8%). Forty (70.0%) had microbiological and/or histological evidence of tuberculosis, and 17 (30.0%) had a diagnosis based on clinical and laboratory data. All patients responded well to initial pericardiocentesis. However, nine patients (16.0%) were lost to follow up. The hospitalisation duration for the steroid groups was shorter than for the placebo group. This difference was not significant. Complications were similar for all arms. Conclusions: Intrapericardial and systemic corticosteroids were well tolerated but did not improve the clinical outcome. The standard six-month regimen was effective regardless of HIV infection. The potential benefits from adjunctive corticosteroids in the management of effusive tuberculous pericarditis could not be demonstrated in this three-year study.en_ZA
dc.format.extentp. 233-238
dc.language.isoen_ZAen_ZA
dc.publisherClinics Cardiv Publishingen_ZA
dc.subjectAdjunctive corticosteroidsen_ZA
dc.subjectTuberculous pericarditis -- Treatmenten_ZA
dc.titleExperience with adjunctive corticosteriods in managing tuberculous pericarditisen_ZA
dc.typeArticleen_ZA
dc.description.versionPublishers' versionen_ZA
dc.rights.holderCardiovascular Journal of Africa holds the copyrighten_ZA


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

ITEM VIEW